AU2022422997A1 - Crystalline form of glp-1 receptor agonist and preparation method therefor - Google Patents

Crystalline form of glp-1 receptor agonist and preparation method therefor Download PDF

Info

Publication number
AU2022422997A1
AU2022422997A1 AU2022422997A AU2022422997A AU2022422997A1 AU 2022422997 A1 AU2022422997 A1 AU 2022422997A1 AU 2022422997 A AU2022422997 A AU 2022422997A AU 2022422997 A AU2022422997 A AU 2022422997A AU 2022422997 A1 AU2022422997 A1 AU 2022422997A1
Authority
AU
Australia
Prior art keywords
compound
crystal form
methyl
characteristic peaks
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022422997A
Other languages
English (en)
Inventor
Zhenxing DU
Weidong Lu
Qiyun SHAO
Gujun XU
Junran YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Pharmaceutical Co Ltd
Publication of AU2022422997A1 publication Critical patent/AU2022422997A1/en
Assigned to JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. reassignment JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. Request for Assignment Assignors: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD., SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2022422997A 2021-12-23 2022-12-23 Crystalline form of glp-1 receptor agonist and preparation method therefor Pending AU2022422997A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111586541 2021-12-23
CN202111586541.3 2021-12-23
PCT/CN2022/141407 WO2023116879A1 (zh) 2021-12-23 2022-12-23 一种glp-1受体激动剂的结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
AU2022422997A1 true AU2022422997A1 (en) 2024-07-11

Family

ID=86901327

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022422997A Pending AU2022422997A1 (en) 2021-12-23 2022-12-23 Crystalline form of glp-1 receptor agonist and preparation method therefor

Country Status (10)

Country Link
US (1) US20250049778A1 (enExample)
EP (2) EP4455140B1 (enExample)
JP (1) JP2024547112A (enExample)
KR (1) KR20240125004A (enExample)
CN (1) CN118401518A (enExample)
AU (1) AU2022422997A1 (enExample)
CA (1) CA3241677A1 (enExample)
MX (1) MX2024007907A (enExample)
TW (1) TW202328115A (enExample)
WO (1) WO2023116879A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025189141A1 (en) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Methods for treating obesity and increasing weight loss

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
JP2023528565A (ja) * 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
PL4157832T3 (pl) * 2020-05-27 2024-12-16 Qilu Regor Therapeutics Inc. Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania
CN119930605A (zh) * 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
WO2022228490A1 (zh) * 2021-04-30 2022-11-03 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
KR20240125004A (ko) 2024-08-19
CN118401518A (zh) 2024-07-26
EP4455140B1 (en) 2026-04-01
US20250049778A1 (en) 2025-02-13
EP4455140A1 (en) 2024-10-30
EP4725484A2 (en) 2026-04-15
EP4455140A4 (en) 2025-04-09
CA3241677A1 (en) 2023-06-29
JP2024547112A (ja) 2024-12-26
TW202328115A (zh) 2023-07-16
WO2023116879A1 (zh) 2023-06-29
MX2024007907A (es) 2024-07-12

Similar Documents

Publication Publication Date Title
EP4455141B1 (en) Pharmaceutically acceptable salt and crystalline form of a glp-1 receptor agonist for the treatment of diabetes
EP4455140B1 (en) Crystalline forms of a glp-1 receptor agonist and preparation methods therefor
EP4332102A1 (en) Isoquinolone compound and use thereof
CN120359210A (zh) Cyp11b2抑制剂化合物、药物组合物及其应用
US20240374581A1 (en) Salt types of tricyclic tetrahydro isoquinoline derivative
JP4605218B2 (ja) キヌクリジン誘導体の新規な塩
EP4538277A1 (en) Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt
EP2099786A1 (en) Process for preparing a crystalline form of candesartan cilexetil
US20250353839A1 (en) Polymorph of benzo[c]chroman compound, preparation method therefor and use thereof
TW202519227A (zh) 稠環衍生物、其製備方法及其在醫藥上的應用
WO2024193455A1 (zh) 一种1,4-二氢-1,6-萘啶酰胺化合物的可药用盐、晶型及其制备方法
TWI914461B (zh) 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法
CN112500353B (zh) 一种左西孟旦的前药化合物、制备方法及其应用
CN114644616B (zh) 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
CN120535504A (zh) 一种p38α-MK2抑制剂的晶型及其制备方法和应用
KR20250174948A (ko) 질소 함유 테트라시클릭 화합물의 결정 형태 및 이의 제조 방법
WO2024159211A1 (en) Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement
CN118556054A (zh) 一种p2x3受体拮抗剂的结晶形式及其制备方法

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

Free format text: FORMER APPLICANT(S): JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.; SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD.